Pegvisomant

Origin and Structure

Pegvisomant is a pegylated growth hormone receptor antagonist developed by Sensus Drug Development and later acquired by Pfizer. The FDA approved it in March 2003 under the trade name Somavert. It is a recombinant variant of human growth hormone engineered from work in the late 1980s and 1990s by John Kopchick and colleagues at Ohio University, who characterized the specific amino-acid substitutions required to convert GH from an agonist to an antagonist.

The molecule carries nine substitutions relative to native GH. Eight of them are in the "binding site 1" region and increase receptor affinity. The critical one — a glycine-to-lysine substitution at position 120 in binding site 2 — prevents the productive dimerization of the receptor that is required for signal transduction. The resulting protein binds the GH receptor tightly but cannot trigger downstream JAK2/STAT5 signaling. To extend its half-life, the molecule is conjugated to four or five polyethylene glycol (PEG) chains of ~5 kDa each, producing the final ~42 kDa pegylated drug product.

Mechanism of Action

Pegvisomant occupies the growth hormone receptor and blocks endogenous GH from binding productively. Two GH receptors must dimerize correctly to activate intracellular JAK2 and phosphorylate STAT5, which in turn drives hepatic IGF-1 production. Pegvisomant binds one receptor monomer normally but the modified second binding site fails to recruit and correctly orient the second monomer, so no signaling occurs. The net result is reduced hepatic IGF-1 production, even though circulating GH levels may actually rise (because negative feedback from IGF-1 on the pituitary is reduced).

IGF-1 — not GH itself — is the main driver of the tissue effects in acromegaly, so normalizing IGF-1 is the clinical endpoint that matters.

Clinical Evidence and Indication

Pegvisomant is approved for acromegaly — the chronic disorder of GH excess almost always caused by a benign pituitary adenoma. First-line therapy is surgical resection; medical therapy is reserved for patients not cured by surgery or unsuitable for it. The available medical classes are somatostatin receptor ligands (octreotide, lanreotide, pasireotide), dopamine agonists (cabergoline), and GH receptor antagonists (pegvisomant).

Pegvisomant's pivotal trial (Trainer et al., NEJM 2000) and the ACROSTUDY post-marketing registry (over 2,000 patients, decade-plus follow-up) established its efficacy:

• IGF-1 normalization. Achieved in roughly 60–70% of patients at standard doses in pivotal trials; real-world registry data shows slightly lower rates consistent with variable adherence and titration.
• Symptomatic improvement. Soft-tissue swelling, headaches, sweating, and joint pain typically improve along with IGF-1.
• Use as monotherapy or combination. Often combined with long-acting somatostatin analogues in patients with partial response to either alone.

Because pegvisomant acts at the peripheral receptor rather than at the pituitary tumor, it does not shrink the underlying adenoma — tumor monitoring with MRI remains part of standard care.

Safety Profile

Pegvisomant's side effect profile is generally more favorable than somatostatin analogues (which cause GI symptoms, cholelithiasis, and glucose abnormalities):

• Hepatotoxicity. Elevated liver enzymes occur in ~5–10% of patients; clinically significant hepatitis is less common but requires monitoring and sometimes discontinuation.
• Injection-site lipohypertrophy. Local fat hypertrophy at injection sites, which is why site rotation is standard.
• Tumor growth concerns. Theoretical; registry data has been generally reassuring but routine MRI surveillance is recommended.

Practical Considerations

Pegvisomant is administered as a daily subcutaneous injection, titrated to IGF-1 normalization — typical doses range from 10 to 30 mg daily, with some patients requiring more. Because GH levels rise on therapy (due to interrupted IGF-1 feedback), GH cannot be used as a treatment-response marker; monitoring is by IGF-1 measurement alone. Cost is high — annual therapy in the U.S. runs into the six figures — and access is through specialty pharmacy channels.

The Bottom Line

Pegvisomant is a mechanistically elegant drug for a rare disease. It is the only GH receptor antagonist in clinical use, and it provides a salvage option for acromegaly patients who fail surgery and are inadequately controlled on somatostatin analogues. It has no role outside acromegaly — it is not a metabolic or anti-aging compound, and any framing in those contexts is a category error. For context on the opposite end of the GH-axis pharmacology, see the GH secretagogues like ipamorelin and tesamorelin.